Deborah Quinn
Overview
Deborah Quinn received an average of $477K in total compensation, including $295K in salary, at Bellerophon Therapeutics from 2015 to 2017.
Source: SEC filings on April 5, 2018 and March 20, 2017.
Related executives
We found seven more executives who work or worked at Bellerophon Therapeutics.
Fabian Tenenbaum
Bellerophon Therapeutics
Chief Executive Officer
Peter Fernandes
Bellerophon Therapeutics
Chief Regulatory and Safety Officer
Assaf Korner
Bellerophon Therapeutics
Chief Financial Officer
Jonathan Peacock
Bellerophon Therapeutics
Chief Executive Officer
Martin Meglasson
Bellerophon Therapeutics
Chief Scientific Officer
Reinilde Heyrman
Bellerophon Therapeutics
former Chief Clinical Development Officer
Martin Dekker
Bellerophon Therapeutics